Free Trial
→ [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (From Crypto Swap Profits) (Ad)

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

Written by MarketBeat Staff
May 18, 2023

Key Points

  • Biotech stocks have a reputation for being high risk, high reward.
  • Many of the stocks Wall Street thinks can double (or better) over the next 12 months are biotechs.
  • Although Denali has yet to commercialize a product, analysts are encouraged by its progress and collaborations with major biopharmaceutical players.
  • Since its May 4th report, seven analysts have reiterated buy ratings on Ultragenyx compared to one hold.
  • 5 stocks we like better than Denali Therapeutics.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.

Should you invest $1,000 in Denali Therapeutics right now?

Before you consider Denali Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.

While Denali Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Denali Therapeutics (DNLI)
4.4645 of 5 stars		$24.36-0.2%N/A-8.83Moderate Buy$38.90
Ultragenyx Pharmaceutical (RARE)
4.6401 of 5 stars		$46.72+0.7%N/A-7.22Moderate Buy$86.69
Sarepta Therapeutics (SRPT)
4.914 of 5 stars		$110.01-0.8%N/A88.01Buy$181.33
Pfizer (PFE)
5 of 5 stars		$24.84-0.4%6.76%33.57Moderate Buy$32.92
Exelixis (EXEL)
4.7763 of 5 stars		$34.74+0.3%N/A22.27Moderate Buy$31.44
Moderna (MRNA)
4.6292 of 5 stars		$36.70-0.6%N/A-6.31Hold$84.00
United Therapeutics (UTHR)
4.5219 of 5 stars		$364.11-0.1%N/A15.99Moderate Buy$370.86
Biogen (BIIB)
4.8648 of 5 stars		$155.69-0.2%N/A14.06Moderate Buy$257.20
Sanofi (SNY)
2.8128 of 5 stars		$47.72-0.1%3.10%24.35Moderate Buy$57.50
Eli Lilly and Company (LLY)
4.9913 of 5 stars		$740.27-1.7%0.70%80.03Moderate Buy$1,007.94
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again
Palantir and the NASDAQ 100: What’s the Next Big Stock Swing for This AI Giant?
Rocket Lab Stock Explodes Higher—What’s Next for This Space Pioneer?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines